Dr. Reddy’s Laboratories surges on launching generic Carboprost Tromethamine injection

09 Dec 2019 Evaluate

Dr. Reddys Laboratories is currently trading at Rs. 2937.00, up by 45.05 points or 1.56% from its previous closing of Rs. 2891.95 on the BSE.

The scrip opened at Rs. 2893.30 and has touched a high and low of Rs. 2942.65 and Rs. 2892.45 respectively. So far 4379 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2990.00 on 27-Nov-2019 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.

Last one week high and low of the scrip stood at Rs. 2969.00 and Rs. 2850.00 respectively. The current market cap of the company is Rs. 48796.60 crore.

The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.04% and 14.03% respectively.

Dr. Reddy's Laboratories has launched in the US generic Carboprost Tromethamine injection used for aborting pregnancy. The company has launched Carboprost Tromethamine injection USP, 250 mcg/mL (1mL) single-dose vial in the US market. The product is a generic version of Pfizer's Hemabate injection in the strength of 250mcg/mL.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharm aceuticals in India and overseas.

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×